Eli Lilly’s profit ... expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity ...

Scotland has become the first country in the UK to back NHS use of Eli Lilly ... for Mounjaro by 25th June, with a final recommendation scheduled for the end of October. Lilly’s head of ...

The Ozempic CKD data, meanwhile, is heading for a final readout next ... candidate for cancer. Lilly’s Mounjaro also growing strongly Also this morning, Eli Lilly reported big sales gains ...

Eli Lilly has begun the week with a bang ... Tirzepatide, the GLP-1 drug in Mounjaro and Zepbound, is Lilly’s highest-profile MASH candidate. Lilly reported phase 2 MASH data in June and ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...

Eli Lilly should continue to grow its top line faster than its similarly sized peers. Its lineup features several blockbusters, including its popular diabetes and weight loss medicines ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend growth stocks. Dividend stocks faced a tough year in 2024 as investor focus ...

Eli Lilly, the American company that makes a rival weight-loss drug called Mounjaro, has also called for the obesity drugs to be listed on the PBS in its pre-budget submission. The Eli Lilly ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...